In a reversed setting, we next investigated CNDAC in a panel consisting of the AML cell line HL-60 and its sublines adapted to the nucleoside analogues cytarabine, Ara-G, azacytidine, and fludarabine, the purine antagonist 6-mercaptopurine, the Bcl-2 inhibitor venetoclax, the PARP inhibitor olaparib, and the polo-like kinase 1 inhibitor volasertib. Here, BCL2 is linked to acute myeloid leukemia.